Mycobutin

Selected form

Rifabutin

Method of action: Antimiycobacterials, Anti-Tuberculosis

Treatment option: Infection, AIDS / HIV

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mycobutin

Quick Facts

Property	Description
Active Ingredient	Rifabutin
Form	Capsules (Oral Formulation)
Pharmacological Class	Antibiotic; Antimycobacterial Agent
General Purpose	To combat specialized bacterial infections
Origin	Synthetic (derived from rifamycins)

What is Mycobutin and Its Core Classification?

Mycobutin is the trade name for the highly specialized, prescription-only medicine whose active pharmacological substance is Rifabutin. It is fundamentally classified as an antibiotic because its function is to kill or inhibit the growth of harmful bacteria.

This medication is uniquely designated as an antimycobacterial agent, which distinguishes it from general antibiotics by its targeted activity against the Mycobacterium family of organisms. Rifabutin belongs to the rifamycins group, a structural subgroup of the broader ansamycins class, defining its chemical heritage and mechanism profile. Rifabutin is an antimicrobial agent used to treat bacterial infections, specifically those caused by mycobacteria. This means the drug's primary role is to fight harmful germs.

Composition, Form, and Origin

The core component of the medicine is Rifabutin, which is a synthetic compound derived from the structure of natural rifamycins. This drug is typically supplied as a solid, single-ingredient product in the form of capsules for oral administration.

As an oral capsule, Mycobutin contains the active substance Rifabutin along with necessary excipients (inactive components) to form the preparation. This formulation is clinically recognized for its ability to penetrate tissues effectively, which is critical for fighting intracellular infections. Its tailored synthetic structure is intended to optimize its effectiveness against difficult-to-treat organisms. Rifabutin is a rifamycin derivative synthesized for enhanced penetration and activity against Mycobacterium avium complex. This structural modification helps the medicine reach the areas where the bacteria are hiding.

General Purpose of Mycobutin

The general purpose of Mycobutin is to serve as a specialized antitubercular agent used to eliminate certain bacterial pathogens. It achieves this by exerting powerful bactericidal activity, meaning it actively kills the target organisms rather than merely slowing their growth.

This medicine’s action is highly specific and critical for combating stubborn mycobacterial infections, such as those that commonly affect immunocompromised individuals. The mechanism involves disrupting vital bacterial production—specifically, by stopping the bacteria from synthesizing the proteins and nucleic acids they need to survive and multiply, positioning it for dedicated therapeutic goals against these resilient pathogens.

Regulatory References

What side effects are possible with Mycobutin?

Possible Side Effects and Safety Information

The safety profile for Mycobutin (Rifabutin) is officially classified by regulatory documents, which detail adverse reactions across various body systems. A notable and expected effect is the red-orange discoloration of body fluids, including urine, tears, and sweat. This effect may permanently stain soft contact lenses.

Adverse reactions are grouped by the physiological system affected, most commonly involving the Blood and Lymphatic System, the Gastrointestinal Disorders, and Eye Disorders.

Official Frequency Classifications

Classification	Representative Adverse Reactions
Very Common	Neutropenia, Leukopenia, Rash, Discolored Urine, Jaundice
Common	Nausea, Vomiting, Diarrhea, Abdominal Pain, Headache, Anemia
Uncommon	Uveitis, Corneal Deposits, Agranulocytosis, Hypersensitivity

Serious Adverse Reactions and Constraints

Regulatory labeling specifies clinically significant events, including Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Serious blood disorders like agranulocytosis and severe intestinal issues like Clostridioides difficile-associated diarrhea (CDAD) are also documented.

Certain safety patterns are noted: the ocular inflammation known as uveitis is associated with higher daily doses of the medicine. Furthermore, the drug is a known inducer of the CYP3A enzyme subfamily, a restriction that may decrease the plasma concentration of other co-administered medications.

Specific monitoring is necessary for patients with severe renal impairment due to increased systemic exposure. The medicine is formally contraindicated in individuals with known hypersensitivity to Rifabutin or any other rifamycin drugs.

Overdose and Emergency Response

Overdose and when to seek help for Mycobutin

The official regulatory documents provide specific information regarding the management of potential Mycobutin (Rifabutin) overdose, particularly emphasizing the regulatory constraints on available human clinical data.

Documented Overdose Profile

Feature	Official Regulatory Statement
Specific Symptoms	No specific experience is documented in treating human Rifabutin overdose. Consequently, the regulatory literature does not formally list specific signs or symptoms of acute toxicity that result from overexposure.
Antidote Availability	No specific antidote is known for Rifabutin overdose, making supportive care the exclusive focus of mandated management.

Emergency Management and Action

When an overdose is suspected, immediate medical attention is required for assessment and procedural intervention. The suggested management procedures are based on general clinical experience with the rifamycin pharmacological class, which governs the immediate actions undertaken by healthcare professionals.

These official procedural measures focus on reducing the absorption of the drug from the gastrointestinal tract. Regulatory information includes the recommendation of gastric lavage to evacuate contents and the use of an activated charcoal slurry to aid in drug absorption from the stomach. Furthermore, it is officially noted that methods such as hemodialysis or forced diuresis are not expected to be effective in enhancing the systemic elimination of the unchanged drug, owing to its high protein binding and extensive tissue distribution.

Therapeutic Uses of Mycobutin

What Mycobutin Treats: Main Uses and Benefits

Mycobutin (Rifabutin) is a specialized antibiotic used primarily to treat and prevent challenging infections caused by the Mycobacterium genus. Its therapeutic benefit is focused on addressing active tuberculosis (TB), it is applied in addressing disseminated Mycobacterium avium complex (MAC) disease, and serving as prophylaxis (prevention) for MAC in immunocompromised patients.

Therapeutic Applications and Symptom Support

This medicine is commonly applied in clinical settings that involve acute or unstable symptom patterns associated with mycobacterial infections. Mycobutin is used for managing symptom clusters related to systemic imbalance, such as persistent fever, night sweats, and weight loss or fatigue. It contributes to easing the overall symptom load in conditions involving inflammatory or irritative processes. For patients, the benefit provided is supportive:

“It assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations associated with these complex infections.”

In immunocompromised individuals, this prophylactic application contributes to improved comfort during symptomatic periods, supporting the patient against the onset of opportunistic infections.

Quick Fact: Support for Systemic Symptom Management
Relevant Clinical Focus	Managing symptoms that interfere with daily functioning, especially systemic signs of active disease.
Symptomatic Benefit	Provides support that helps ease the overall symptom burden and assists with maintaining stability.

Regulatory References

NIH DailyMed drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Mycobutin?

Eligibility for Mycobutin (Rifabutin) is strictly defined by regulatory documents based on patient history, age, physiological status, and comorbidity. Use is generally established for adults but is restricted or prohibited for several defined populations.

Contraindications and Prohibited Use

Mycobutin is absolutely contraindicated for patients with a known history of hypersensitivity (allergic reaction) to Rifabutin itself or to any other drug in the rifamycin class, such such as rifampin. The medicine is also prohibited for patients with a diagnosis of active porphyria.

Restricted and Conditional Eligibility

Pediatric Patients: Use for the prevention of Mycobacterium avium complex (MAC) disease has not been established in children under 18 years of age.
Renal or Hepatic Impairment: Patients with severe renal impairment or hepatic impairment require caution and close monitoring.
Pregnancy and Lactation: Use during pregnancy is conditional, advised only if the benefit outweighs the potential risk. Use is not recommended while breastfeeding, requiring discontinuation of nursing or the medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mycobutin (rifabutin) has a high potential for clinically significant drug interactions, primarily because it is a potent inducer of the Cytochrome P450 3A (CYP3A) enzyme system. This induction effect leads to a substantial decrease in the plasma concentrations of many coadministered medicines that are metabolized by this enzyme. Examples include oral contraceptives, certain antiretroviral agents (e.g., protease inhibitors), some anticoagulants, and corticosteroids.

Conversely, Mycobutin itself is also metabolized by CYP3A. Concomitant use with strong CYP3A inhibitors, such as certain macrolides (e.g., clarithromycin) and many azole antifungals (e.g., fluconazole, voriconazole), will increase the plasma concentrations of rifabutin and its active metabolite, potentially elevating the risk of adverse effects like uveitis.

Specific combinations are officially contraindicated (not to be used together) due to severe loss of therapeutic effect or increased toxicity, including coadministration with certain hepatitis C antivirals and certain rilpivirine formulations. Dosage adjustments are often required for both rifabutin and the coadministered drug when specific antiretrovirals or other interacting agents are used simultaneously. Patients should be aware of the need for rigorous monitoring during combination therapy.

Mechanism of Action

Selective Inhibition of Bacterial Genetic Transcription

The mechanism of Mycobutin (rifabutin) relies on highly specific biological actions that collectively contribute to bactericidal action against susceptible pathogens. The molecule functions as a selective inhibitor by binding tightly to the Beta Subunit of the bacterial DNA-dependent RNA Polymerase (RNAP). This physical interaction halts the process of transcription, shutting down the synthesis of essential messenger RNA (mRNA). This molecular event stops the pathogen from producing the proteins required for survival, resulting in direct cell death.

Targeted Intracellular Penetration for Pathogen Reduction

The drug's high lipophilicity is a critical mechanistic feature that allows it to achieve high concentrations within the host's macrophages, the very immune cells where mycobacteria are frequently localized intracellularly. This unique property enables the drug to access and act upon the bacteria at their protected site, thereby contributing to the reduction of the pathogen load at the cellular level.

Dosage and Administration Information

How to Use Mycobutin (Rifabutin): Administration Guidelines

Mycobutin is available as 150 mg oral capsules and is administered by the oral route. The following instructions outline dosing and administration.

Standard Dosing and Frequency

The standard adult dose for prophylaxis against Mycobacterium avium complex (MAC) is 300 mg once daily. This is typically achieved by taking two 150 mg capsules at the same time each day.

Dosing Situation	Standard Instruction
Frequency	Once daily (QD).
Alternative Frequency	150 mg twice daily (BID) if gastrointestinal upset occurs.
With Meals	May be taken with or without food.

Administration and Adjustments

Capsules should generally be swallowed whole. For patients with difficulty swallowing, the contents of the capsules may be mixed with a small amount of soft food, such as applesauce, and consumed immediately.

Dosage adjustments are specifically mandated in certain situations:

Severe Renal Impairment: Dosing should be reduced by 50% (e.g., 150 mg daily) if drug toxicity is suspected in patients with severe kidney disease (creatinine clearance <30 mL/min).
Drug Interactions: The Mycobutin dose must be substantially reduced when co-administered with strong CYP3A4 inhibitors (e.g., certain protease inhibitors), potentially requiring a regimen of 150 mg every other day.
Missed Dose: If a dose is missed, individuals should take the next scheduled dose and should not double the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Mycobutin

Evidence for Preventing Disseminated MAC Disease

Research explored the role of Mycobutin in the context of preventing a severe, widespread infection known as disseminated Mycobacterium avium Complex (MAC) disease. The core research for this purpose involved randomized, double-blind, placebo-controlled trials (RCTs) conducted across multiple medical centers. These multi-center studies research examined adult patients with advanced HIV infection and very low immune cell counts.

The primary thing researchers were looking for was the incidence of MAC bacteremia, which is a microbiological outcome describing the presence of MAC bacteria in the blood. The findings described patterns observed in the studies regarding the incidence of MAC bacteremia compared to the placebo group. This research contributes to the broader evidence landscape by examining prevention strategies for MAC.

What remains uncertain is the effect of the medicine on patient survival. While studies explored this outcome, the initial analysis of the blinded trials did not establish a statistically significant difference in survival between the study groups. Furthermore, long-term effects are not fully established, and existing studies provide limited insight into the optimal time point to initiate prophylaxis.

Research for Treating Active Tuberculosis (TB)

Research examined regimens for treating Active Tuberculosis (TB) that incorporated Mycobutin as part of a multi-drug combination. Studies often took the form of randomized, controlled studies where regimens including this medicine were compared to regimens using rifampin, a commonly used anti-TB drug. The research focused specifically on populations with newly diagnosed pulmonary TB.

The main outcomes research examined were sputum conversion rates, a microbiological measure of clearing the bacteria. Studies described patterns where regimens including Mycobutin often reported the microbiological outcome (sputum conversion) at a similar frequency compared to regimens using rifampin.

Research limitations frames show that a lack of large-scale non-inferiority RCTs still exists, particularly for co-infected patients receiving modern combination antiretroviral therapy (cART). Findings were mixed regarding the risk of the bacteria developing resistance, with some studies describing patterns of elevated risk when the medicine was observed in regimens that used non-daily dosing in immunocompromised populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Mycobutin (FAQ)

Q: How long do I need to take Mycobutin for MAC prophylaxis?

A: Official guidelines indicate that when used for the prevention of disseminated Mycobacterium avium complex (MAC) disease, treatment is generally continued until the risk of a widespread infection is considered low. The duration of the regimen is determined by a healthcare professional and is not a fixed length of time.

Q: Can I stop taking my birth control pill while on Mycobutin?

A: Regulatory documents indicate that Mycobutin can reduce the effectiveness of hormonal contraceptives, such as birth control pills. This is due to the way Mycobutin affects the enzymes that break down these hormones. Official product information notes the need to consider using additional or alternative non-hormonal methods of contraception.

Q: Is Mycobutin safe to use during pregnancy?

A: According to official information, this drug should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. There are currently no adequate human studies available to accurately determine the drug-associated risk. Any decision regarding its use during pregnancy should be made after consulting a healthcare professional.

Q: Can children take Mycobutin?

A: The safety and effectiveness of Mycobutin for the prevention of MAC disease have not been established in children younger than 18 years of age. Limited safety data exist regarding its use for treating MAC in children who are HIV-positive. Any decision regarding use in pediatric patients must be made by a qualified healthcare professional.

Q: Why does Mycobutin turn my urine and tears orange?

A: The red-orange discoloration of body fluids, including urine, sweat, and tears, is a commonly noted effect of this medication. This color change is caused by the drug being naturally excreted by the body. The discoloration is a known, expected effect associated with the drug's excretion, but it may permanently stain soft contact lenses.

Q: Is Mycobutin the same as Rifampin?

A: Rifabutin (the active ingredient in Mycobutin) and Rifampin are both antibiotics that belong to the same pharmacological class, known as the rifamycins. While they share a common chemical structure and similar mechanism of action, they have distinct medical indications and notable differences in how they interact with other medicines.

Q: What is the trade name for the drug Rifabutin?

A: The primary, well-known trade name for the active ingredient Rifabutin is Mycobutin. Rifabutin is a specialized, prescription-only antibiotic used for combating specific bacterial infections.

Q: Does Mycobutin make you drowsy?

A: Drowsiness (somnolence) is not typically listed as a common or very common adverse reaction in official product labeling. However, other effects on the nervous system have been reported, such as headache and difficulty sleeping (insomnia).

How should Mycobutin be stored and disposed of?

Storage and Disposal of Mycobutin (Rifabutin)

Mycobutin capsules must be stored at controlled room temperature, which is officially defined as being between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted up to 30 C.

The medication must be stored in a tightly closed container to preserve its integrity. It is a mandatory requirement that Mycobutin be kept out of the reach of children.

Disposal

Unused or expired product should be disposed of strictly according to local regulations and requirements. For healthcare settings, the label specifies following institutional procedures for pharmaceutical or antineoplastic waste when discarding unused Mycobutin.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.